Pacific Edge SPP Closes; $20.7m Of Total New Equity Pledged

4 AUGUST 2025



PACIFIC EDGE SPP CLOSES; $20.7 MILLION OF TOTAL NEW
EQUITY PLEDGED
DUNEDIN, New Zealand – On 13 May 2025, cancer diagnostics company Pacific Edge
Limited (“Pacific Edge”, the “Company”) (NZX, ASX: PEB) announced a $20.0 million capital
raise comprising a $15.0 million placement and a $5.0 million Share Purchase Plan (“SPP”).
The SPP closed on 31 July 2025, with subscriptions for ~$4.7 million of new ordinary shares.
The Directors have resolved to accept all eligible SPP applications in full.
The proceeds from the SPP, combined with an associated ~$16.1 million Placement that
preceded it, brings the new equity committed to the company to $20.7 million in aggregate.
This is greater than the $20.0 million initially sought as the Placement was upsized after
Directors resolved to accept oversubscriptions.
The Placement is conditional on shareholder approval, which is to be sought at the Annual
Shareholders’ Meeting on 6 August 2025. The issue of shares under the SPP is conditional on
the Placement becoming unconditional.
Subject to these conditions being met, the 207,350,411 new shares will be issued at $0.10 per
share. All shares issued as part of the Placement and the SPP are expected to be allotted to
participants on 13 August 2025 and will rank equally with all ordinary shares on issue on that
date.
KEY DATES OF THE SPP*
DATE EVENT DESCRIPTION
6 August 2025 Annual
Shareholders’
Meeting
Shareholders’ meeting to, amongst
other things, approve the Placement.
13 August 2025 Allotment Date and
commencement of
trading on NZX
Shares are allotted under the
Placement and the SPP.
Trading of the Shares is expected to
commence on the NZX Main Board
on the Allotment Date and on ASX on
the business day following the
Allotment Date.
13 August 2025 Holding Statements Holding Statements are sent to
Applicants who are allotted Shares
under the SPP.
* Subject to the NZX and ASX Listing Rules and applicable laws, Pacific Edge reserves the right to alter any dates
for the SPP.
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

2

For more information:
Investors: Media:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: 022 032 1263
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of
urothelial cancer in patients presenting with microhematuria and those being monitored for
recurrent disease. The tests help improve the overall patient experience, while prioritizing time
and clinical resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than
25 peer reviewed publications, and Cxbladder Triage is now included in the American
Urological Association’s Microhematuria Guideline. To drive increased adoption and improved
patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies
designed to generate further clinical utility evidence.
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and
South America. In the US, the test has been used by over 5,000 urologists who have ordered
more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the
population via public healthcare and all residents have the option of buying the test online.